Genmab A/S (GMAB) Insider Transactions
Track insider buying and selling at Genmab A/S. 5 transactions on record — real-time MAR Art.19 data from Danish FSA.
Last updated: 2026-05-24
Real-time filings with conviction scores, signal badges, and post-trade performance tracking.
Recent insider transactions at Genmab A/S
| Date | Insider | Role | Type | Shares | Price | Value | Signals |
|---|---|---|---|---|---|---|---|
| 2026-04-01 | Jan van de Winkel | BUY | 8,525 | DKK 1.8K | DKK 14.99M | 📉 📅 | |
| 2026-03-02 | Jan van de Winkel | Board Member | BUY | 567 | DKK 1.9K | DKK 1.06M | 📉 📅 |
| 2026-02-19 | Anthony Pagano | SELL | 899 | DKK 1.8K | DKK 1.63M | — | |
| 2025-12-01 | Deirdre P. Connelly | Chairman | BUY | 378 | DKK 2.0K | DKK 772.3K | — |
| 2025-11-19 | Martin Schultz | Board Member | SELL | 42 | DKK 2.0K | DKK 82.3K | — |
Named insiders at Genmab A/S
About Genmab A/S insider disclosures
InsidersAlpha tracks 5 disclosed insider transactions at Genmab A/S sourced from Danish FSA. Of these, 3 are purchase transactions and 2 are sales. All data is sourced from official regulatory filings under MAR Article 19 and updated daily.
The largest single transaction recorded was worth DKK 14.99M by Jan van de Winkel on 2026-04-01.
Insider trading disclosures at Genmab A/S are filed with Danish FSA within 3 business days of each transaction, as required by the EU Market Abuse Regulation (MAR) Article 19.
Frequently asked questions
Who are the insiders at Genmab A/S?
Insiders at Genmab A/S who have disclosed transactions include: Jan van de Winkel, Anthony Pagano, Deirdre P. Connelly, Martin Schultz. These are PDMRs (Persons Discharging Managerial Responsibilities) who filed with Danish FSA under MAR Article 19.
When was the last insider buy at Genmab A/S?
The most recent insider purchase at Genmab A/S was by Jan van de Winkel on 2026-04-01, worth DKK 14.99M. InsidersAlpha updates daily from official Danish FSA disclosures.
Is Genmab A/S stock a buy based on insider activity?
InsidersAlpha tracks 5 insider transactions at Genmab A/S. Of these, 3 are purchases and 2 are sales (60% buy ratio). Insider activity is moderately bullish — more buying than selling. Past performance does not guarantee future results — always conduct your own research.
Where is Genmab A/S listed?
Genmab A/S (GMAB) is listed on Nasdaq Copenhagen in Denmark. Insider transactions are disclosed to Danish FSA under MAR Article 19.